
U.S. Food and Drug Administration Approves Biosimilar Rituximab-pvvr (Ruxience) for CD20-positive non-Hodgkin B-cell Lymphomas and Chronic Lymphocytic Leukemia
On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab
Read More >